Add to a list

Inactive Instrument

Rubius Therapeutics Stock

RUBY

US78116T1034

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Latest news : Rubius Therapeutics

23-04-06	Rubius Therapeutics, Inc. Announces Resignation of Pablo J. Cagnoni, M.D. as Member of Board of Directors	CI
23-03-09	Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from S&P TMI Index	CI
23-03-06	Upcoming Powell Testimony to Congress Underpins US Equity Futures	MT
23-03-06	Top Premarket Decliners	MT
23-03-06	Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from NASDAQ Composite Index	CI
23-03-06	Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell 3000E Index	CI
23-03-06	Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell Microcap Value Index	CI
23-03-06	Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell 3000E Value Index	CI
23-03-06	Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell Microcap Index	CI
23-03-03	Rubius Therapeutics, Inc. Announces Board Changes	CI
23-03-03	Rubius Therapeutics, Inc. Announces CEO Changes	CI
23-02-27	Rubius Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-02-26	Rubius Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI

More news

Analysts' recommendations: Rubius Therapeutics

22-09-13	Guggenheim Downgrades Rubius Therapeutics to Neutral From Buy	MT
22-09-09	Morgan Stanley Cuts Price Target on Rubius Therapeutics to $1.50 From $2, Maintains Equalweight Rating	MT
22-04-11	SVB Leerink Adjusts Rubius Therapeutics' Price Target to $3 From $5, Keeps Market Perform Rating	MT
22-04-11	Morgan Stanley Adjusts Price Target on Rubius Therapeutics to $4 From $15, Keeps Equalweight Rating	MT
22-04-11	Guggenheim Adjusts Rubius Therapeutics' Price Target to $5 From $25, Keeps Buy Rating	MT

More recommendations

Press Releases: Rubius Therapeutics

23-04-06	RUBIUS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
23-03-03	RUBIUS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)	AQ
23-02-27	RUBIUS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
23-02-22	RUBIUS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23-02-06	RUBIUS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)	AQ

More press releases

Managers and Directors: Rubius Therapeutics

Manager	Title	Age	Since
Craig Jalbert PSD	President	64	2023-03-03
Lori Murray IRC	Investor Relations Contact	-	2018-05-31
James Jogerst PRN	Corporate Officer/Principal	-	2021-08-29

Director	Title	Age	Since
Craig Jalbert BRD	Director/Board Member	64	2023-03-03

More insiders

Rubius Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing a platform and pipeline that is focused on creating cellular medicines called Red Cell Therapeutics. The Company's Red Cell Therapeutics are engineered to express biotherapeutic proteins within or on their cell surface to create selective and allogeneic cellular medicines for treating a range of diseases. Red Cell Therapeutics can also be used to kill tumors in cancer, regulate the immune system for the treatment of autoimmune diseases and treat a number of other types of illnesses. The Company's subsidiary is Rubius Therapeutics Securities Corporation.

Employees

Sector

More about the company

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-02-23	Dannielle Appelhans	Sell	Chief Executive Officer	10,385	0.0115%
23-01-31	Pablo Cagnoni	Sell	Chief Executive Officer	8,448	0.0093%
23-01-30	Dannielle Appelhans	Fiscal year	Chief Executive Officer	18,878	0.0209%

Rubius Therapeutics Stock

Stocks

RUBY

US78116T1034

Latest news : Rubius Therapeutics

Analysts' recommendations: Rubius Therapeutics

Press Releases: Rubius Therapeutics

Quotes and Performance

Managers and Directors: Rubius Therapeutics

Latest insider transactions

Company Profile